IRIS
ROSSARI, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.629
EU - Europa 1.180
AS - Asia 976
SA - Sud America 163
Continente sconosciuto - Info sul continente non disponibili 112
AF - Africa 18
OC - Oceania 2
Totale 4.080
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.564
RU - Federazione Russa 658
SG - Singapore 360
IT - Italia 279
CN - Cina 245
BR - Brasile 133
BD - Bangladesh 113
HK - Hong Kong 79
VN - Vietnam 78
DE - Germania 49
FR - Francia 43
GB - Regno Unito 42
CA - Canada 34
IN - India 29
NL - Olanda 27
JP - Giappone 22
MX - Messico 17
AR - Argentina 13
PL - Polonia 12
SE - Svezia 12
ES - Italia 9
FI - Finlandia 9
AT - Austria 7
ZA - Sudafrica 7
LT - Lituania 6
PK - Pakistan 6
CH - Svizzera 5
ID - Indonesia 5
SA - Arabia Saudita 5
TR - Turchia 5
BE - Belgio 4
CO - Colombia 4
GR - Grecia 4
IQ - Iraq 4
MA - Marocco 4
MY - Malesia 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
EG - Egitto 3
JM - Giamaica 3
NP - Nepal 3
SI - Slovenia 3
SV - El Salvador 3
VE - Venezuela 3
AU - Australia 2
EC - Ecuador 2
GT - Guatemala 2
HN - Honduras 2
IE - Irlanda 2
IR - Iran 2
NI - Nicaragua 2
PE - Perù 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
UA - Ucraina 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CG - Congo 1
CL - Cile 1
CR - Costa Rica 1
CY - Cipro 1
HR - Croazia 1
IL - Israele 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
KR - Corea 1
LK - Sri Lanka 1
MD - Moldavia 1
MM - Myanmar 1
MV - Maldive 1
PH - Filippine 1
PR - Porto Rico 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
UY - Uruguay 1
Totale 3.968
Salva come PNG Salva come JPEG
Città #
Dallas 840
Singapore 234
Moscow 120
Ashburn 98
Hong Kong 75
San Jose 65
Beijing 61
New York 60
Milan 54
Council Bluffs 53
Los Angeles 46
Santa Clara 31
Ho Chi Minh City 28
Rome 25
Orem 23
Lauterbourg 21
Munich 18
Tokyo 18
São Paulo 17
Hanoi 16
Naples 16
Hefei 14
Shanghai 14
Montreal 13
Poplar 13
Atlanta 11
London 11
Manchester 11
Chicago 10
Denver 10
Frankfurt am Main 10
Mexico City 10
Warsaw 10
Toronto 9
Brooklyn 8
Phoenix 8
Boardman 7
Cesano Boscone 7
Chennai 7
Guangzhou 7
Monza 7
Amsterdam 6
Bacoli 6
Bari 6
Berlin 6
Biên Hòa 6
Nuremberg 6
Secaucus 6
Stockholm 6
Boston 5
Charlotte 5
Dhaka 5
Helsinki 5
Houston 5
Newark 5
North Bergen 5
West Palm Beach 5
Belo Horizonte 4
Catania 4
Da Nang 4
Genoa 4
Johannesburg 4
Milwaukee 4
Mumbai 4
New Delhi 4
Omaha 4
Padua 4
Palermo 4
Querétaro 4
Rio de Janeiro 4
Riyadh 4
San Francisco 4
Tianjin 4
Verona 4
Vinh 4
Athens 3
Bologna 3
Brescia 3
Buenos Aires 3
Buffalo 3
Ljubljana 3
Nanning 3
Pelotas 3
Porto Alegre 3
San Salvador 3
Schafisheim 3
Shenzhen 3
São José dos Campos 3
Trieste 3
Venice 3
Vienna 3
Vilnius 3
Washington 3
Agadir 2
Ankara 2
Bangkok 2
Belford Roxo 2
Brunswick 2
Brussels 2
Cape Coral 2
Totale 2.344
Salva come PNG Salva come JPEG
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 437
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 422
Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models 179
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 148
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 141
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 140
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 135
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 123
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 123
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 122
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 122
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 116
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 115
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 115
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 111
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 109
The transcription factor HIF2α partakes in the differentiation block of acute myeloid leukemia 109
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer 106
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 105
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 98
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 95
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 89
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 85
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 83
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 81
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 80
Treatment options for advanced hepatocellular carcinoma: the potential of biologics 78
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 76
A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice 76
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 74
Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-Tnf: Neutrophil-To-lymphocyte ratio and platelet-To-lymphocyte ratio 71
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 59
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 27
Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study 8
null 7
Tumor-targeted cytokine delivery by engineered myeloid cells unlocks CAR T cell efficacy and endogenous T cell responses in glioblastoma 6
Gene-based delivery of immune-activating cytokines for cancer treatment 5
Comprehensive genetic analysis in biliary tract cancer: a prospective single-center experience 4
Totale 4.080
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.572
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.572
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202316 2 3 0 2 2 1 1 0 2 3 0 0
2023/202442 0 1 5 2 5 4 0 0 0 2 8 15
2024/2025273 18 4 3 13 20 19 30 49 21 15 19 62
2025/20263.467 157 443 589 357 253 119 164 225 636 136 175 213
2026/2027281 168 113 0 0 0 0 0 0 0 0 0 0
Totale 4.080